Abstract 46P
Background
The drug resistance against chemotherapy and high metastasis rate in triple-negative breast cancer reduce the success of breast cancer treatment. Glutathione S-transferase P1 enzyme (GSTP1) expression increases in cancer cell lines and leads to the development of drug resistance against chemotherapy. The antioxidant chlorophyllin is shown to have an inhibitory effect on GSTP1. The purpose of this study is to investigate the effects of GSTP1 inhibitor chlorophyllin and/or its coadministration with anticancer drug docetaxel on metastatic processes in vitro/in vivo in the 4T1 triple-negative breast cancer cell line and animal model.
Methods
Cell viability, cell cycle, and cell migration were investigated by MTT test, flow cytometry, and wound closure assay, respectively. Matrix metalloproteinase 9 (MMP-9) expression, causing invasion, was determined by Western Blot in the 4T1 cell line and tissue samples. Further, total gelatinase enzyme activity was also detected by gelatin degradation assay. Total GST enzyme activity and glutathione levels of tissue were investigated by colorimetric methods. Micrometastatic foci in liver tissue sections were evaluated by histochemistry.
Results
As a result, coadministration of chlorophyllin and docetaxel significantly inhibited cell migration in vitro. Chlorophyllin significantly reduced the expression of MMP-9 in the tissue samples, and this effect was higher when it is coadministered with docetaxel. In coadministration, a significant decrease was observed in the total gelatinase activity in vivo. It was also determined that chlorophyllin increased in vivo total glutathione levels and decreased GST enzyme activity. Finally, the micrometastases in the liver were reduced by coadministration.
Conclusions
Our results suggest that the coadministration of chlorophyllin and docetaxel may have a potential role in the control of metastatic processes by suppressing cell migration and invasion which is mainly characterized by gelatinase enzyme expression & activity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University Scientific Research Projects Coordination Unit.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09